Lilly CEO David Ricks (Photographer: David Paul Morris/Bloomberg via Getty Images)
March 28, 2022 02:30 PM EDT
R&D
Pharma

Eli Lil­ly ver­sus the 800-pound go­ril­la in atopic der­mati­tis? It may just have a shot — at 2nd place

John Carroll

Editor & Founder

Eli Lil­ly turned a few heads when the mar­ket ma­jor bought out the IL-13 le­brik­izum­ab for $1.1 bil­lion a lit­tle more than 2 years ago …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times